BACKGROUND: The overexpression of ATP-binding cassette (ABC) transporters is one of the main causes of multi-drug resistance (MDR) which represents a major obstacle to the success of cancer chemotherapy. In this study, we examined the effect of BIBF 1120, an inhibitor of vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs) and fibroblast growth factor receptors (FGFRs) tyrosine kinases, on the reversal of multidrug resistance in vitro. METHODS: The doxorubicin and rhodamine 123 retention assay was performed by flowcytometry. Western blot were employed to identify ABCB1 expression level and the effect of BIBF 1120 on the blockade of Akt and ERK1/2 phosphorylation. The expression of mdr1 mRNA was determined by RT-PCR analysis. The ATPase activity of ABCB1 was investigated using Pgp-Glo™ assay systems. RESULTS: BIBF 1120 significantly enhanced the cytotoxicity of doxorubicin and paclitaxel and increased the accumulation of ABCB1 substrates in ABCB1-overexpressing cancer cells, whereas it had no effect on the parental cells. On the other hand, BIBF 1120 did not alter the cytotoxicity of non-ABCB1 substrates and was unable to reverse ABCC1 or ABCG2-mediated MDR. Furthermore, BIBF 1120 inhibited the ATPase activity of ABCB1 in a concentration-dependent manner. However, no detectable alteration on the expression level of mdr1 mRNA or ABCB1 protein was identified in ABCB1-overexpressing cancer cells by different treatments of BIBF 1120. Interestly, total and phosphorylated forms of AKT and ERK1/2 were not inhibited by BIBF 1120 at the reversal concentrations. CONCLUSION: Our results suggest that BIBF 1120 is capable of overcoming ABCB1-mediated drug resistance by inhibiting ABCB1 function, which may have clinical significance for BIBF 1120 combinational treatment of certain resistant cancers.
BACKGROUND: The overexpression of ATP-binding cassette (ABC) transporters is one of the main causes of multi-drug resistance (MDR) which represents a major obstacle to the success of cancer chemotherapy. In this study, we examined the effect of BIBF 1120, an inhibitor of vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs) and fibroblast growth factor receptors (FGFRs) tyrosine kinases, on the reversal of multidrug resistance in vitro. METHODS: The doxorubicin and rhodamine 123 retention assay was performed by flowcytometry. Western blot were employed to identify ABCB1 expression level and the effect of BIBF 1120 on the blockade of Akt and ERK1/2 phosphorylation. The expression of mdr1 mRNA was determined by RT-PCR analysis. The ATPase activity of ABCB1 was investigated using Pgp-Glo™ assay systems. RESULTS:BIBF 1120 significantly enhanced the cytotoxicity of doxorubicin and paclitaxel and increased the accumulation of ABCB1 substrates in ABCB1-overexpressing cancer cells, whereas it had no effect on the parental cells. On the other hand, BIBF 1120 did not alter the cytotoxicity of non-ABCB1 substrates and was unable to reverse ABCC1 or ABCG2-mediated MDR. Furthermore, BIBF 1120 inhibited the ATPase activity of ABCB1 in a concentration-dependent manner. However, no detectable alteration on the expression level of mdr1 mRNA or ABCB1 protein was identified in ABCB1-overexpressing cancer cells by different treatments of BIBF 1120. Interestly, total and phosphorylated forms of AKT and ERK1/2 were not inhibited by BIBF 1120 at the reversal concentrations. CONCLUSION: Our results suggest that BIBF 1120 is capable of overcoming ABCB1-mediated drug resistance by inhibiting ABCB1 function, which may have clinical significance for BIBF 1120 combinational treatment of certain resistant cancers.
Authors: Francis J Giles; William T Bellamy; Zeev Estrov; Susan M O'Brien; Srdan Verstovsek; Farhad Ravandi; Miloslav Beran; Paul Bycott; Yazdi Pithavala; Heidi Steinfeldt; Steven D Reich; Alan F List; Karen W L Yee Journal: Leuk Res Date: 2005-12-05 Impact factor: 3.156
Authors: Gergely Szakács; Jean-Philippe Annereau; Samir Lababidi; Uma Shankavaram; Angela Arciello; Kimberly J Bussey; William Reinhold; Yanping Guo; Gary D Kruh; Mark Reimers; John N Weinstein; Michael M Gottesman Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: Christiane Knuefermann; Yang Lu; Bolin Liu; Weidong Jin; Ke Liang; Ling Wu; Mathias Schmidt; Gordon B Mills; John Mendelsohn; Zhen Fan Journal: Oncogene Date: 2003-05-22 Impact factor: 9.867
Authors: Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman Journal: Nat Rev Drug Discov Date: 2006-03 Impact factor: 84.694
Authors: Niranjan Awasthi; Stefan Hinz; Rolf A Brekken; Margaret A Schwarz; Roderich E Schwarz Journal: Cancer Lett Date: 2014-12-16 Impact factor: 8.679
Authors: G Bousquet; J Alexandre; C Le Tourneau; F Goldwasser; S Faivre; H de Mont-Serrat; R Kaiser; J L Misset; E Raymond Journal: Br J Cancer Date: 2011-10-25 Impact factor: 7.640
Authors: Gustavo Jabor Gozzi; Amanda do Rocio Andrade Pires; Glaucio Valdameri; Maria Eliane Merlin Rocha; Glaucia Regina Martinez; Guilhermina Rodrigues Noleto; Alexandra Acco; Carlos Eduardo Alves de Souza; Aurea Echevarria; Camilla Moretto Dos Reis; Attilio Di Pietro; Sílvia Maria Suter Correia Cadena Journal: PLoS One Date: 2015-06-17 Impact factor: 3.240
Authors: Kareem Ebeid; Xiangbing Meng; Kristina W Thiel; Anh-Vu Do; Sean M Geary; Angie S Morris; Erica L Pham; Amaraporn Wongrakpanich; Yashpal S Chhonker; Daryl J Murry; Kimberly K Leslie; Aliasger K Salem Journal: Nat Nanotechnol Date: 2017-12-04 Impact factor: 39.213
Authors: Mohamed I Attia; Wagdy M Eldehna; Samar A Afifi; Adam B Keeton; Gary A Piazza; Hatem A Abdel-Aziz Journal: PLoS One Date: 2017-07-25 Impact factor: 3.240
Authors: Bernhard Englinger; Daniela Lötsch; Christine Pirker; Thomas Mohr; Sushilla van Schoonhoven; Bernd Boidol; Charles-Hugues Lardeau; Melanie Spitzwieser; Pál Szabó; Petra Heffeter; Irene Lang; Margit Cichna-Markl; Bettina Grasl-Kraupp; Brigitte Marian; Michael Grusch; Stefan Kubicek; Gergely Szakács; Walter Berger Journal: Oncotarget Date: 2016-08-02